Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

Journal of Clinical Oncology

Volumn 13, Issue 12, 1995, Pages 2944-2953

  Sridhara, Rajeshwari ^a   Eisenberger, Mario A ^b   Sinibaldi, Victoria J ^b   Reyno, Leonard M ^b   Egorin, Merrill J ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; HYDROCORTISONE; PROSTATE SPECIFIC ANTIGEN; SURAMIN; TUMOR MARKER; VITAMIN K GROUP;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER HORMONE THERAPY; CLINICAL TRIAL; DIAGNOSIS; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SURVIVAL;

EID: 0028862179     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.12.2944     Document Type: Article

References (30)

1. Yagoda A: Response in prostalic cancer: An enigma. Semin Urol 1:311-319, 1984
2. Schmidt JD, Gibbons RP, Johnson DE: Chemotherapy of advanced prostate cancer. Evaluation of response parameters. Urology 7:602-610, 1976
3. Inde DC, Bunn PA, Cohen MH: Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with Adriamycin and cyclophosphamide. Methods of documenting tumor response and progression. Cancer 45:1300-1310, 1980
4. Logothetis CJ, Samuels ML, Von Echenback AC: Doxorubicin, mitomycin C, and 5-fluorouracil in the treatment of metastatic hormone-refractory adenocarcinoma of the prostate with a note on the staging of metastatic prostate cancer. J Clin Oncol 1:368-378, 1983
5. Eisenberger M: Chemotherapy for prostate carcinoma. The NCI consensus for the treatment of prostate cancer. NCI Monogr 7:151-163, 1988
6. Takayama TK, Vessella RL, Lange PH: Newer applications of serum PSA in the management of prostatic cancer. Semin Oncol 21:542-553, 1994
7. Desterling J: Prostate specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:905-923, 1991
8. Miller JI, Ahmann FR, Drach GW, et al: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147:956-961, 1992
9. Scher HI, Curley T, Geller N, et al: Trimetrexate in prostate cancer: Preliminary observation on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8:1830-1838, 1990
10. Kelly WMK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
11. Eisenberger MA, Reyno LM, Jodrell DI, et al: Suramin, an active drug for prostate cancer: Interim observations in a phase I trail. J Natl Cancer Inst 85:611-621, 1993
12. Jodrell DI, Reyno LM, Sridhara R, et al: Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 12:166-175, 1994
13. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone refractory prostate cancer. J Clin Oncol (in press)
14. Reyno LM, Egorin MJ, Eisenberger MA. et al: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-2196, 1995
15. Kaplan E. Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Mantel N, Haenzel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
17. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
18. Breiman L, Friedman JH, Olshen RA, et al: Classification and Regression Trees. Monterey, CA, Wadsworth International, 1984
19. Steele G Jr. Ellenberg S, Ramming K, et al: CEA monitoring among patients in multi-institutional adjuvant GI therapy protocols. Ann Surg 196:162-169, 1982
20. Tanner WP Jr, Swets JA: A decision-making theory of visual detection. Psychol Rev 61:401-409, 1954
21. Schatzkin A, Freedman LS, Schiffman MH, et al: Validation of intermediate end points in cancer research. J Natl Cancer Inst 82:1746-1752, 1990
22. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
23. Herson J: The use of surrogate endpoints in clinical trials (an introduction to a series of four papers). Stat Med 8:403-404, 1989
24. Ellenberg SS, Hamilton JM: Surrogate endpoints in clinical trials: cancer. Stat Med 8:405-413, 1989
25. Wittes J, Lakatos E, Probstfield J: Surrogate endpoints in clinical trails: Cardiovascular diseases. Stat Med 8:415-425, 1989
26. Hillis A, Seigel D: Surrogate endpoints in clinical trials: Ophthalmologic disorders. Stat Med 8:427-430, 1989
27. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431-440, 1989
28. Thibault A, Sartor O, Cooper MR, et al: A 75% decline in prostate-specific antigen (PSA) predicts survival in hormone refractory prostate cancer. Proc Am Assoc Cancer Res 34:192, 1993 (abstr)
29. Gail MH: Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 37:67-78, 1981
30. George SL: Statistical considerations and modeling of clinical utility of tumor markers. Hematol Oncol Clin North Am 8:457-470, 1994